Related Experiment Video
Updated: Apr 8, 2026
Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
Published on: September 3, 2020
The Clinical Status of Stem Cell Therapy for Ischemic Cardiomyopathy
Xianyun Wang1, Jun Zhang1, Fan Zhang1
1Cell Therapy Laboratory, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China.
Insights
Stem cell therapy shows promise for ischemic cardiomyopathy (ICM). Challenges like low cell survival and delivery methods need addressing for effective cardiac repair in heart disease patients.
Area of Science:
- Cardiovascular Research
- Regenerative Medicine
- Stem Cell Biology
Background:
- Ischemic cardiomyopathy (ICM) is a major global health concern, driving significant morbidity and mortality.
- Stem cell therapy is an emerging and promising treatment strategy for ICM, with various cell types investigated.
- Current therapeutic approaches face challenges, including low survival rates of transplanted cells in the damaged heart muscle.
Purpose of the Study:
- To provide an overview of different stem cell types used in ICM treatment.
- To discuss the advantages and disadvantages of various stem cell therapies.
- To analyze the current therapeutic potential and future prospects of stem cell translation for ischemic heart disease.
Main Methods:
- Review of existing clinical research on stem cell applications in ICM.
- Analysis of stem cell types such as cardiac-derived stem cells (CSCs), mesenchymal stem cells (MSCs), and others.
- Evaluation of factors influencing therapeutic efficacy, including delivery route, cell type, dosage, and timing.
Main Results:
- Multiple stem cell types (CSCs, MSCs, etc.) have been explored for ICM treatment.
- Therapeutic effects are attributed to cell transdifferentiation and paracrine signaling.
- Key challenges include poor stem cell survival and integration within the infarcted myocardium.
Conclusions:
- Stem cell therapy holds significant potential for treating ischemic cardiomyopathy.
- Addressing limitations in cell survival, delivery, and patient-specific factors is crucial for clinical advancement.
- Further research and optimization are needed to establish stem cell translation as an ideal future therapy for ischemic heart disease.
Abstract:
Ischemic cardiomyopathy (ICM) is becoming a leading cause of morbidity and mortality in the whole world. Stem cell-based therapy is emerging as a promising option for treatment of ICM. Several stem cell types including cardiac-derived stem cells (CSCs), bone marrow-derived stem cells, mesenchymal stem cells (MSCs), skeletal myoblasts (SMs), and CD34(+) and CD 133(+) stem cells have been applied in clinical researches. The clinical effect produced by stem cell administration in ICM mainly depends on the transdifferentiation and paracrine effect. One important issue is that low survival and residential rate of transferred stem cells in the infracted myocardium blocks the effective advances in cardiac improvement. Many other factors associated with the efficacy of cell replacement therapy for ICM mainly including the route of delivery, the type and number of stem cell infusion, the timing of injection, patient's physical condition, the particular microenvironment onto which the cells are delivered, and clinical condition remain to be addressed. Here we provide an overview of the pros and cons of these transferred cells and discuss the current state of their therapeutic potential. We believe that stem cell translation will be an ideal option for patients following ischemic heart disease in the future.
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
01:30Cardiomyopathy II: Dilated Cardiomyopathy